The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension
AbstractA culture of exercise testing is firmly embedded in the management of pulmonary arterial hypertension (PAH) but its clinical relevance and utility have recently been under some debate. The six minute walk test (6MWT) has been used as a primary outcome measure to enable the licensing of many of the medications used for this condition. Recent reviews have questioned the validity of this test as a surrogate of clinical outcomes. At the same time, other questions are emerging where exercise testing may be the solution. With the rise in understanding of genetic markers of idiopathic PAH (IPAH), the screening of an otherwise healthy population for incipient pulmonary hypertension (PH) will be required. The proliferation in treatment choices and identification of populations with PH where PAH treatment is not indicated, such as left heart and lung disease, requires more definitive differentiation from patients with PAH. There is a continuing question about the existence and clinical relevance of exercise induced PAH as a cause of unexplained dyspnoea and fatigue and as a latent phase of resting PH. This review presents a summary and critical analysis of the current role of exercise testing in PAH and speculates on future trends. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Johnson, M.K.; Thomson, S. The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension. Diseases 2014, 2, 120-147.
Johnson MK, Thomson S. The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension. Diseases. 2014; 2(2):120-147.Chicago/Turabian Style
Johnson, Martin K.; Thomson, Stephen. 2014. "The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension." Diseases 2, no. 2: 120-147.